Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder | Zendy

Julie Rask Larsen | Zendy; Louise Vedtofte | Zendy; Mathilde S. L. Jakobsen | Zendy; Hans Søe Riis Jespersen | Zendy; Michelle Iris Jakobsen | Zendy; Camilla Kara Svensson | Zendy; Kamuran Koyuncu | Zendy; Ole Schjerning | Zendy; Peter Oturai | Zendy; Andreas Kjær | Zendy; Jimmi Nielsen | Zendy; Jens J. Holst | Zendy; Claus Thorn Ekstrøm | Zendy; Christoph U. Correll | Zendy; Tina Vilsbøll | Zendy; Anders FinkJensen | Zendy

Open Access

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder

Author(s) -

Julie Rask Larsen,

Louise Vedtofte,

Mathilde S. L. Jakobsen,

Hans Søe Riis Jespersen,

Michelle Iris Jakobsen,

Camilla Kara Svensson,

Kamuran Koyuncu,

Ole Schjerning,

Peter Oturai,

Andreas Kjær,

Jimmi Nielsen,

Jens J. Holst,

Claus Thorn Ekstrøm,

Christoph U. Correll,

Tina Vilsbøll,

Anders FinkJensen

Publication year - 2017

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2017.1220

Subject(s) - liraglutide , medicine , olanzapine , population , clozapine , placebo , overweight , schizoaffective disorder , antipsychotic , body mass index , prediabetes , type 2 diabetes , schizophrenia (object oriented programming) , endocrinology , diabetes mellitus , psychosis , psychiatry , environmental health , alternative medicine , pathology

Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research